Entering text into the input field will update the search result below

Cel-Sci: LEAPS And COVID-19

Mar. 10, 2020 1:53 PM ETCEL-SCI Corporation (CVM)25 Comments


  • CEL-SCI announced that it is developing an immunotherapy for COVID-19 based on its LEAPS peptide technology.
  • CEO  says the company is currently in talks with multiple healthcare partners to expeditiously develop the therapy.
  • •LEAPS/COVID-19 technology has unique characteristics that give it favorable advantages in the COVID-19 management space.


CEL-SCI is a small-cap market (~$500 million) clinical-stage cancer bio-pharmaceutical company. It has two products in the pipeline: Multikine and LEAPS.

Multikine, a cocktail combination of cytokines and chemokines, is a prospective neoadjuvant treatment and an investigational drug candidate in Phase III Event-Driven clinical development for newly diagnosed advanced primary head and neck cancer.

The goal of Multikine is to boost the body's immune system prior to Standard of Care (“SOC”). The Event-Driven Phase III study is fully enrolled with 928 patients, and the last patient was treated in September 2016.

To prove an overall survival benefit, the study requires CEL-SCI to wait until 298 events (deaths) have occurred among the two main comparator groups. We believe that this 9-year Phase III trial has just ended or will end very soon. Thus, top line results are imminent.

But Multikine was really the only game in town, until today!


LEAPS has been on the back-burner for years so that the company could focus on Multikine.

The Ligand Antigen Epitope Presentation System ("LEAPS") platform technology has demonstrated in several animal models the ability to design antigen-specific immunotherapeutic peptides that preferentially direct the immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed response and are also capable of enhancing important T-regulatory (Treg) responses. Therefore, the LEAPS technology provides the opportunity to develop immunotherapeutic products for diseases for which disease associated antigenic peptide((s)) sequences have already been identified, such as: a number of infectious diseases, some cancers, autoimmune diseases (e.g., RA), allergic asthma and allergy, select CNS diseases (e.g., Alzheimer's) and the COVID-19 virus.

The Company's LEAPS technology is also being developed as a therapeutic vaccine for rheumatoid arthritis and is supported by $1.5 million grant for IND enabling studies from the National Institute of Arthritis and Musculoskeletal and Skin

This article was written by

I am an avid investor of Biotechs. CVM set me up for life despite the results.  Having swing shares in addition to a core and selling covered calls is critical to successful investing.  Know when to SELL!

Analyst’s Disclosure: I am/we are long CVM. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.